Autologous neutralizing antibody responses after antiretroviral therapy in acute and early HIV-1
Open Access
- 23 April 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (11)
Abstract
BACKGROUND: Early antiretroviral therapy initiation (ARTi) in HIV-1 restricts reservoir size and diversity while preserving immune function, potentially improving opportunities for immunotherapeutic cure strategies. For antibody-based cure approaches, the development of autologous neutralizing antibodies (anAbs) after acute/early ARTi is relevant but is poorly understood. METHODS: We characterized antibody responses in a cohort of 23 participants following ARTi in acute HIV (<60 days after acquisition) and early HIV (60–128 days after acquisition). RESULTS: Plasma virus sequences at the time of ARTi revealed evidence of escape from anAbs after early, but not acute, ARTi. HIV-1 envelopes representing the transmitted/founder virus(es) (acute ARTi) or escape variants (early ARTi) were tested for sensitivity to longitudinal plasma IgG. After acute ARTi, no anAb responses developed over months to years of suppressive ART. In 2 of the 3 acute ARTi participants who experienced viremia after ARTi, however, anAbs arose shortly thereafter. After early ARTi, anAbs targeting those early variants developed between 12 and 42 weeks of ART and continued to increase in breadth and potency thereafter. CONCLUSION: Results indicate a threshold of virus replication (~60 days) required to induce anAbs, after which they continue to expand on suppressive ART to better target the range of reservoir variants. TRIAL REGISTRATION: ClinicalTrials.gov NCT02656511. FUNDING: NIH grants U01AI169767, R01AI162646, UM1AI164570, UM1AI164560, U19AI096109, K23GM112526, T32AI118684, P30AI045008, P30AI027763, R24AI067039; Gilead Sciences grant INUS2361354; Viiv Healthcare grant A126326.Keywords
Funding Information
- National Institutes of Health (U01AI169767)
- National Institutes of Health (R01AI162646)
- National Institutes of Health (UM1AI164570)
- National Institutes of Health (U19AI096109)
- National Institutes of Health (K23GM112526)
- National Institutes of Health (T32AI118684)
- Gilead Sciences (INUS2361354)
- ViiV Healthcare (A126326)
This publication has 95 references indexed in Scilit:
- Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virionsProceedings of the National Academy of Sciences, 2003
- Antibody neutralization and escape by HIV-1Nature, 2003
- Rapid evolution of the neutralizing antibody response to HIV type 1 infectionProceedings of the National Academy of Sciences, 2003
- Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120Journal of Virology, 2003
- HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sitesNature, 2002
- Neutralizing Antibodies Associated with Viremia Control in a Subset of Individuals after Treatment of Acute Human Immunodeficiency Virus Type 1 InfectionJournal of Virology, 2001
- Antibody from Patients with Acute Human Immunodeficiency Virus (HIV) Infection Inhibits Primary Strains of HIV Type 1 in the Presence of Natural-Killer Effector CellsJournal of Virology, 2001
- Selective Increases in HIV-Specific Neutralizing Antibody and Partial Reconstitution of Cellular Immune Responses during Prolonged, Successful Drug Therapy of HIV InfectionAIDS Research and Human Retroviruses, 2001
- Decay characteristics of HIV-1-infected compartments during combination therapyNature, 1997
- STUDIES OF THE NATURAL HISTORY OF HERPES SIMPLEX INFECTIONSPediatrics, 1953